Last $115.39 USD
Change Today +1.20 / 1.05%
Volume 1.1M
VRTX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

vertex pharmaceuticals inc (VRTX) Snapshot

Open
$114.68
Previous Close
$114.19
Day High
$116.27
Day Low
$113.89
52 Week High
11/19/14 - $118.17
52 Week Low
04/15/14 - $59.79
Market Cap
27.8B
Average Volume 10 Days
1.5M
EPS TTM
$-1.72
Shares Outstanding
240.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERTEX PHARMACEUTICALS INC (VRTX)

vertex pharmaceuticals inc (VRTX) Related Businessweek News

View More BusinessWeek News

vertex pharmaceuticals inc (VRTX) Details

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing other research and early-stage development programs. It markets KALYDECO to treat patients of six years of age and older with CF who have specific genetic mutations in their cystic fibrosis transmembrane conductance (CFTR) regulator gene in the United States, European Union, and Canada. The company also provides INCIVEK in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus infection, as well as markets telaprevir in other international markets. In addition, it is developing Ivacaftor in combination with CFTR corrector compounds, which has completed Phase III development program; and evaluating VX-661, a second investigational CFTR corrector, in combination with ivacaftor in Phase II clinical development. The company identifies and develops next-generation CFTR corrector compounds that evaluate in regimens combining ivacaftor with two CFTR corrector compounds. Further, it is involved in various other research and early-stage development programs, including programs in the areas of oncology, multiple sclerosis, and other serious and rare diseases. The company sells its products principally to major and selected regional wholesalers and specialty pharmacy providers in North America, as well as government-owned and supported customers in Europe. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

1,800 Employees
Last Reported Date: 02/11/14
Founded in 1989

vertex pharmaceuticals inc (VRTX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $583.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $553.8K
Chief Legal Officer and Executive Vice Presid...
Total Annual Compensation: $465.0K
Compensation as of Fiscal Year 2013.

vertex pharmaceuticals inc (VRTX) Key Developments

Vertex Pharmaceuticals Incorporated Presents at BIO-Europe 2014, Nov-03-2014 04:00 PM

Vertex Pharmaceuticals Incorporated Presents at BIO-Europe 2014, Nov-03-2014 04:00 PM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany. Speakers: Benjamin Gannon, Senior Director, Government Affairs and Public Policy.

Vertex Pharmaceuticals Incorporated Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revised Revenue Guidance for 2014

Vertex Pharmaceuticals Incorporated reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported GAAP revenues of $179 million, including revenues of $127 million from KALYDECO(R) (ivacaftor), compared with $221.7 million in total revenues for the third quarter of 2013. The GAAP net loss attributable to the company was $170.1 million, or $0.72 per share, which includes net charges of $84 million. Third quarter 2013 net loss was $124.1 million, or $0.54 per share, including net charges of $49.7 million. The non-GAAP net loss attributable to the company was $86.2 million, or $0.37 per diluted share for the third quarter of 2013. The increased non-GAAP net loss for the third quarter of 2014 was primarily the result of a reduction in INCIVEK net product revenues, partially offset by increased KALYDECO product revenues, decreased operating expenses and the revenues from a one-time payment of $30 million from Janssen related to the out-licensing of VX-787. Total non-GAAP revenues for the third quarter of 2014 were $165.0 million, including $126.8 million in net product revenues from KALYDECO and $38.2 million from royalties and collaborative revenues, which includes revenues from a one-time payment of $30 million from Janssen related to the out-licensing of VX-787 for the treatment of influenza. Loss from operations was $142.20 million compared to $123.56 million reported a year ago. Loss from continuing operations before benefit from income taxes was $166.6 million compared to $118.90 million reported a year ago. Loss from continuing operations was $169.99 million or $0.72 per diluted share compared to $121.45 million or $0.53 per diluted share reported a year ago. On non GAAP basis, the company reported loss from operations of $58.44 million compared to $75.03 million reported a year ago. Non GAAP loss from continuing operations before benefit from income taxes was $82.81 million compared to $70.4 million reported a year ago. Non GAAP net loss from continuing operations was $86.23 million compared to $72.93 million reported a year ago. For the nine months, the company reported total revenues of $435.86 million compared to $860.82 million reported a year ago. Loss from operations was $538.79 million compared to $599.73 million reported a year ago. Loss from continuing operations before benefit from income taxes was $556.28 million compared to $606.47 million reported a year ago. Loss from continuing operations was $561.19 million or $2.40 per diluted share compared to $482.70 million or $2.17 per diluted share reported a year ago. Net loss attributable to the company was $561.99 million or $2.40 per diluted share compared to $489.31 million or $2.20 per diluted share reported a year ago. On non GAAP basis, the company reported loss from operations of $320.24 million compared to $60.02 million reported a year ago. Non GAAP loss from continuing operations before benefit from income taxes was $374.42 million compared to $62.86 million reported a year ago. Non GAAP net loss from continuing operations was $379.34 million compared to $66.67 million reported a year ago. Non GAAP net loss attributable to the company was $379.34 million or $1.62 per diluted share compared to $74.88 million or $0.34 per diluted share reported a year ago. On May 1, 2014, the company provided guidance for 2014 total non-GAAP revenues of $520 million to $550 million, including total 2014 KALYDECO net product revenues of $470 million to $500 million. The company now expects total non-GAAP revenues to be $525 million to $535 million, with KALYDECO net product revenues expected to be approximately $460 million. The KALYDECO net product revenues range was based on assumptions of the timing of label expansion and reimbursement approvals in certain countries, and the company now expects KALYDECO revenues to be below the range provided in May due primarily to the delay in the reimbursement of KALYDECO in Australia.

Vertex Pharmaceuticals Incorporated Announces U.S. Food and Drug Administration's Pulmonary Allergy Drugs Advisory Committee to Recommend Approval of KALYDECO(R) (Ivacaftor)

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration's Pulmonary Allergy Drugs Advisory Committee (PADAC) voted 13-2 to recommend approval of KALYDECO(R) (ivacaftor) in people with cystic fibrosis (CF) ages 6 and older who have the R117H mutation in the cystic fibrosis transmembrane regulatory (CFTR) gene, which is the indication being reviewed by the FDA. Advisory committees provide the FDA with independent scientific and medical advice on safety, effectiveness and appropriate use of potential new medicines. The FDA is not bound by the committee's recommendation, but often follows its advice. The FDA is expected to make a decision on the approval of ivacaftor by December 30, 2014 under the Prescription Drug User Fee Act (PDUFA). Cystic fibrosis is caused by a defective or missing CFTR protein resulting from mutations in the CFTR gene. KALYDECO is currently approved to treat more than 2,600 people ages 6 and older in North America, Europe and Australia who have specific mutations in the CFTR gene. In the United States, these mutations include G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P and G1349D. In people with the R117H mutation, the CFTR protein reaches the cell surface but does not function properly. Approximately 500 people ages 6 and older have this mutation in the United States. Ivacaftor (150 mg tablets) is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. In the United States, ivacaftor is also indicated for the treatment of CF in patients age 6 and older who have one of the following mutations in the CFTR gene: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. In Canada, ivacaftor is indicated for these same mutations and additionally for G970R. Ivacaftor is not effective in patients with CF with 2 copies of the F508del mutation (F508del/F508del) in the CFTR gene. The safety and efficacy of ivacaftor in children with CF younger than 6 years of age have not been established. Use of ivacaftor with medicines that are strong CYP3A inducers, such as the antibiotics rifampin and rifabutin; seizure medications (phenobarbital, carbamazepine, or phenytoin); and the herbal supplement St. John's Wort, substantially decreases exposure of ivacaftor and may diminish effectiveness. Therefore, co-administration is not recommended. The dose of ivacaftor must be adjusted when used concomitantly with strong and moderate CYP3A inhibitors or when used in patients with moderate or severe hepatic disease. Ivacaftor can cause serious adverse reactions including abdominal pain and high liver enzymes in the blood. The most common side effects associated with ivacaftor include headache; upper respiratory tract infection (the common cold), including sore throat, nasal or sinus congestion, and runny nose; stomach (abdominal) pain; diarrhea; rash; and dizziness. These are not all the possible side effects of ivacaftor. A list of the adverse reactions can be found in the product labeling for each country where ivacaftor is approved. Patients should tell their healthcare providers about any side effect that bothers them or does not go away.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRTX:US $115.39 USD +1.20

VRTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $55.01 USD +0.84
BioMarin Pharmaceutical Inc $89.38 USD -0.07
Jazz Pharmaceuticals PLC $176.65 USD +6.22
Regeneron Pharmaceuticals Inc $415.84 USD +2.84
Sigma-Aldrich Corp $136.53 USD -0.02
View Industry Companies
 

Industry Analysis

VRTX

Industry Average

Valuation VRTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.6x
Price/Book 24.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 32.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERTEX PHARMACEUTICALS INC, please visit www.vrtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.